Good's buffer based highly biocompatible ionic liquid modified PLGA nanoparticles for the selective uptake in cancer cells
Good's buffer based highly biocompatible ionic liquid modified PLGA nanoparticles for the selective uptake in cancer cells
复制标题
Goods 缓冲液基于高度生物相容性离子液体修饰的 PLGA 纳米颗粒，用于癌细胞的选择性摄取
DOI：
10.1039/d3qm00787a
复制
发表时间：
2023
影响因子：
7
通讯作者：
Tanner, Eden E.
中科院分区：
文献类型：
--
作者：
Singh, Gagandeep;Dasanayake, Gaya S.;Chism, Claylee M.;Vashisth, Priyavrat;Kaur, Amandeep;Misra, Sandeep Kumar;Sharp, Joshua S.;Tanner, Eden E.
实现安全有效的药物输送仍然是一个突出的挑战。在此，我们合成了 20 种生物相容性产品的基于缓冲液的离子液体 (GBIL)，它们对于药物输送应用具有一系列有吸引力的特性。合成的 GBIL 通过纳米沉淀超声处理涂覆在聚乳酸-乙醇酸 (PLGA) 表面，并通过动态光散射 (DLS) 和质子核磁共振 (1H NMR) 光谱进行表征。然后测试 GBIL 修饰的 PLGA NP 与生物界面的相互作用，例如从人和 BALB/c 小鼠血液中分离的血清蛋白（使用 SDS-PAGE 和 LCMS）和红细胞 (RBC)。在本报告中，我们表明，与人类正常健康乳腺细胞 (MCF-10A) 相比，用某些 GBIL 对 PLGA 进行表面修饰可调节人类三阴性乳腺癌细胞 (MDA-MB-231) 的优先细胞摄取。例如，与 MCF-10A 细胞 (27.3 ± 0.7%) 相比，胆碱 N,N-双(2-羟乙基)-2-氨基乙磺酸盐 (CBES) 包被的 PLGA NP 对 MDA-MB-231 细胞 (60.7 ± 0.7%) 具有选择性。通过这种方式，GBIL 涂层将癌细胞中 PLGA NP 的摄取增加了 2 倍，同时减少了正常健康乳腺细胞的摄取。因此，GBIL 修饰的纳米颗粒可能成为靶向药物输送和基因治疗应用的多功能平台，因为它们的表面特性可以定制以与特定细胞受体相互作用并增强细胞摄取。这种制剂技术在靶向特定细胞方面显示出有希望的结果，可以进一步探索其他细胞类型，以实现治疗剂的位点特异性和有效递送。
Achieving safe and efficacious drug delivery is still an outstanding challenge. Herein we have synthesized 20 biocompatible good's buffer-based ionic liquids (GBILs) with a range of attractive properties for drug delivery applications. The synthesized GBILs were used to coat the surface of poly(lactic-co-glycolic acid) (PLGA) by nanoprecipitation-sonication and characterized by dynamic light scattering (DLS) and proton nuclear magnetic resonance (1H NMR) spectroscopy. The GBIL-modified PLGA NPs were then tested for their interaction with bio-interfaces such as serum proteins (using SDS-PAGE and LCMS) and red blood cells (RBCs) isolated from human and BALB/c mouse blood. In this report, we show that surface modification of PLGA with certain GBILs led to modulation of preferential cellular uptake towards human triple-negative breast cancer cells (MDA-MB-231) compared to human normal healthy breast cells (MCF-10A). For example, cholinium N,N-bis(2-hydroxyethyl)-2-aminoethane sulfonate (CBES) coated PLGA NPs were found to be selective for MDA-MB-231 cells (60.7 ± 0.7%) as compared to MCF-10A cells (27.3 ± 0.7%). In this way, GBIL-coatings have increased PLGA NP uptake in the cancer cells by 2-fold while decreasing the uptake towards normal healthy breast cells. Therefore, GBIL-modified nanoparticles could be a versatile platform for targeted drug delivery and gene therapy applications, as their surface properties can be tailored to interact with specific cell receptors and enhance cellular uptake. This formulation technique has shown promising results for targeting specific cells, which could be explored further for other cell types to achieve site-specific and efficient delivery of therapeutic agents.